Literature DB >> 23169504

Bevacizumab-associated osteonecrosis of the wrist and knee in three pediatric patients with recurrent CNS tumors.

Jason Fangusaro1, Sridharan Gururangan, Regina I Jakacki, Sue C Kaste, Stewart Goldman, Ian F Pollack, James M Boyett, Larry E Kun.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23169504      PMCID： PMC3532396          DOI： 10.1200/JCO.2012.43.6733

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  32 in total

1.  Osteonecrosis of the jaw in a patient with advanced non-small-cell lung cancer receiving bevacizumab.

Authors:  Stamatis Katsenos; Charalampos Christophylakis; Konstantinos Psathakis
Journal:  Arch Bronconeumol       Date:  2012-03-17       Impact factor: 4.872

2.  Bevacizumab (Avastin): An anti-angiogenic drug associated with osteonecrosis of the jaw.

Authors:  Richard L Wynn
Journal:  Gen Dent       Date:  2011 Nov-Dec

3.  Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor.

Authors:  Y S Lin; C Nguyen; J L Mendoza; E Escandon; D Fei; Y G Meng; N B Modi
Journal:  J Pharmacol Exp Ther       Date:  1999-01       Impact factor: 4.030

Review 4.  Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody.

Authors:  A M Ryan; D B Eppler; K E Hagler; R H Bruner; P J Thomford; R L Hall; G M Shopp; C A O'Neill
Journal:  Toxicol Pathol       Date:  1999 Jan-Feb       Impact factor: 1.902

Review 5.  VEGF blocking therapy in the treatment of cancer.

Authors:  Julia Glade-Bender; Jessica J Kandel; Darrell J Yamashiro
Journal:  Expert Opin Biol Ther       Date:  2003-04       Impact factor: 4.388

Review 6.  The pathogenesis of osteonecrosis and the relationships to corticosteroids.

Authors:  R Mirzai; C Chang; A Greenspan; M E Gershwin
Journal:  J Asthma       Date:  1999       Impact factor: 2.515

Review 7.  Anti-angiogenic therapies for children with cancer.

Authors:  Nicolas André; Arnauld Verschuur; Jochen Rossler; Jaroslav Sterba
Journal:  Curr Cancer Drug Targets       Date:  2010-12       Impact factor: 3.428

8.  Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study.

Authors:  Julia L Glade Bender; Peter C Adamson; Joel M Reid; Lu Xu; Sylvain Baruchel; Yuval Shaked; Robert S Kerbel; Erin M Cooney-Qualter; Diana Stempak; Helen X Chen; Marvin D Nelson; Mark D Krailo; Ashish M Ingle; Susan M Blaney; Jessica J Kandel; Darrell J Yamashiro
Journal:  J Clin Oncol       Date:  2008-01-20       Impact factor: 44.544

Review 9.  Monoclonal antibodies as effective therapeutic agents for solid tumors.

Authors:  Yuji Hinoda; Shigeru Sasaki; Tadao Ishida; Kohzoh Imai
Journal:  Cancer Sci       Date:  2004-08       Impact factor: 6.716

Review 10.  Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies.

Authors:  Stacey D Zondor; Patrick J Medina
Journal:  Ann Pharmacother       Date:  2004-06-08       Impact factor: 3.154
View more
  4 in total

1.  Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).

Authors:  Jason Fangusaro; Sridharan Gururangan; Tina Young Poussaint; Roger E McLendon; Arzu Onar-Thomas; Katherine E Warren; Shengjie Wu; Roger J Packer; Anu Banerjee; Richard J Gilbertson; Regina Jakacki; Amar Gajjar; Stewart Goldman; Ian F Pollack; Henry S Friedman; James M Boyett; Larry E Kun; Maryam Fouladi
Journal:  Cancer       Date:  2013-09-19       Impact factor: 6.860

2.  Bevacizumab-associated osteonecrosis of the femur and tibia.

Authors:  Leandro J C Oliveira; Felipe S N A Canedo; Karina P Sacardo; João V M Alessi; Felipe G Barbosa; Andrea K Shimada; Artur Katz
Journal:  Oxf Med Case Reports       Date:  2019-05-31

3.  Magnetic resonance imaging is the preferred method to assess treatment-related skeletal changes in children with brain tumors.

Authors:  Sue C Kaste; Robert A Kaufman; Amar Gajjar; Alberto Broniscer
Journal:  Pediatr Blood Cancer       Date:  2013-03-22       Impact factor: 3.167

4.  Current and emerging treatment strategies for children with progressive chiasmatic-hypothalamic glioma diagnosed as infants: a web-based survey.

Authors:  Amedeo A Azizi; Antoinette Y N Schouten-van Meeteren
Journal:  J Neurooncol       Date:  2017-10-25       Impact factor: 4.130
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.